Mold-Tek Pack. Q1 FY27 Earnings Call — Analysis (NSE: MOLDTKPAC)
Turnover crosses ₹300 Cr for the first time; EBITDA/kg surges to ₹46.7 driven by pharma, consolidation, and raw-material pass-through despite war disruptions.
The take
Q1FY27 Revenue ₹300.45 Cr ( +24.9% YoY ) . New guidance — FY27 pharma segment revenue ₹50-55 Cr . New story: Pharma and medical devices premiumisation .
Results
Revenue ₹300.45 Cr +24.9% YoY; EBITDA/kg at ₹46.7 vs FY26 average of ₹40.7; net profit ₹25.57 Cr +17.35% YoY; volume growth tempered to 6% due to 17% drop in lube.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹300.45 Cr | +24.9% | yoy · Q1FY27 |
| Net Profit | ₹25.57 Cr | +17.35% | yoy · Q1FY27 |
| EBITDA per kg | ₹46.7 | +₹6 | yoy · Q1FY27 · vs FY26 full-year average of ₹40.7 |
| Volume Growth | 6% | yoy · Q1FY27 | |
| Paint Volume Growth | 10.8% | yoy · Q1FY27 | |
| Pharma Revenue Growth | 41% | yoy · Q1FY27 | |
| Food & FMCG Revenue Growth | 24% | yoy · Q1FY27 | |
| Lube Volume Growth | -17% | yoy · Q1FY27 | |
| IML Share (volume) | 75.8% | point_in_time · Q1FY27 · as of Q1FY27 | |
| IML Share (value) | 77.8% | point_in_time · Q1FY27 · as of Q1FY27 | |
| Q1 FY27 Capex | ₹20-22 Cr | point_in_time · Q1FY27 · incurred during quarter |
Guidance
FY27 EBITDA/kg raised to ₹44-45 (earlier ₹42-43) on sustained consolidation benefits and mix shift; full-year volume growth ~10%, capex trimmed to ~₹90 Cr.
What management committed to
- Paint's share in total revenue will decline from current 50% to ~40% in 3-4 years, driven by faster growth in Food & FMCG and pharma. — ~40%, FY30
- Pharma revenue will reach ₹50-55 Cr in FY27, a ~50% YoY growth over FY26's ₹34 Cr. — ₹50-55 Cr, FY27
- FY27 EBITDA per kg will be ₹44-45, surpassing the earlier guidance of ₹42-43. — ₹44-45, FY27
- Full-year volume growth will be ~10% (9-10% range), supported by double-digit paint growth, pharma/Food & FMCG momentum, and lube recovery. — ~10%, FY27
- [Paint] volume growth for FY27 will be in the 10-15% range, driven by Asian Paints' increasing IML adoption and overall demand. — 10-15%, FY27
- FY27 capex will be ~₹90 Cr, reduced from the earlier run-rate of ₹130-135 Cr; includes ₹25-30 Cr for pharma/medical devices, rest for maintenance and debottlenecking. — ~₹90 Cr, FY27
- Ophthalmic packaging commercial molds will arrive in 5-6 months, enabling product launch at the beginning of calendar year 2027 (Q4FY27). — Q4FY27
- If a tie-up with a foreign IP holder for dosing pens materializes, [Mold-Tek] will enter the pens business within one year; otherwise, internal development will take 2-3 years. — FY28
- Vibe JV will commence commercial production in Q3FY27 and generate revenue of a couple of crores in Q4FY27. — couple of crores, Q4FY27
- Lube volumes will normalise in Q2FY27 as affected clients have arranged alternative base-oil supplies. — Q2FY27
- FY27 EBITDA growth will be 18-20% YoY, outpacing volume growth due to mix shift and operating efficiencies. — 18-20%, FY27
Key themes
Mix-shift to high-margin pharma/FMCG and consolidation-driven margin expansion
How the narrative shifted
- Pharma and medical devices premiumisation: Mold-Tek is pivoting aggressively toward high-margin pharma and adjacent medical devices, viewing current penetration as just the tip of a large opportunity.
- Consolidation-driven structural margin gain: The closure of three Hyderabad units and consolidation into two is a permanent efficiency lever, delivering ~₹3/kg incremental EBITDA that will not revert.
- Mix shift from paint/lube to pharma/food: Higher growth in Food & FMCG and pharma is structurally reducing the share of lower-margin paint and volatile lube, improving blended realisation and EBITDA/kg even with moderate volume growth.
- Raw material pass-through resilience: Despite a ~50% spike in PP prices due to war, the company could pass through cost increases within a month, protecting and even enhancing margins – a testament to client relationships.
- Lube disruption as a transitory war impact: The 17% lube volume drop is attributed entirely to client base-oil shortages from Iran conflict; normalisation expected in Q2 as alternative supplies arranged.
- Capex discipline and asset sweating: Management is lowering FY27 capex to ~₹90 Cr while focusing on sweating existing assets to push utilisation beyond 75%, signalling capital efficiency and free-cash-flow orientation.
- New high-value adjacencies (Vibe, ophthalmic, pens, semi-con): Beyond pharma, the company is seeding multiple high-value platforms (dosing pens, semiconductor trays) that could transform the revenue mix in 3-5 years, with Vibe as the nearest proof point.
Operational commentary
- Consolidation of Hyderabad operations from 5 to 2 units completed; reduced overheads, inter-unit transfers, and rejections, driving a permanent ₹3/kg EBITDA uplift.
- Pharma remains the highest-margin growth vector: 41% revenue growth in Q1; target FY27 revenue ₹50-55 Cr (+50% YoY); 25+ clients active, 10 more visiting.
- New pharma-adjacent pipeline: ophthalmic packaging trial molds ready, commercial molds arriving in 5-6 months (launch early CY27); medical dosing pens being pursued with potential IP tie-up to cut development from 3 years to 1 year.
- Food & FMCG grew 24% YoY; thin-wall penetration expanding in North (Panipat) and South (Cheyyar); Panipat doubling thin-wall capacity from Aug-26 for festive season.
- Qpack volume flat (+2%) due to price sensitivity in edible oil/cashew after raw-material spike; recovery expected as RM stabilises and North/South capacities ramp.
- Lube segment down 17% YoY because major private clients faced base-oil disruption from Iran war; alternative supply arrangements now in place, volumes seen normalising in Q2.
- Vibe JV: 3 products patented, 3 more in pilot; commercial production expected Q3FY27, high-value-add (EBITDA at least parity with pharma), meaningful contribution from FY28.
- Capacity utilisation at 75%; management aiming 78-80% via debottlenecking and better plant loading; 10-12% annual capacity addition planned.
- Automation and lean-manufacturing study trip to China planned; implementation expected to further reduce rejections and manpower costs over next two quarters.
- Capex discipline: FY27 capex lowered to ~₹90 Cr (vs ₹130-135 Cr earlier), comprising ₹25-30 Cr for pharma/medical devices and balance for maintenance/debottlenecking.
Analyst Q&A
Q. What drove the 6% volume growth and how sustainable is the EBITDA/kg of ₹46.7?
Volume dragged by 17% drop in lube due to client base-oil disruption; ex-lube growth would have been 9%. EBITDA/kg uplift from permanent consolidation benefits, better capacity utilisation, and mix improvement — ₹3 from pharma/FMCG and ₹3 from consolidation. Full-year target raised to ₹44-45.
Q. Qpack volume growth of only 2% — reasons and recovery outlook?
Qpack is price-sensitive; edible oil/cashew clients hesitated after RM spike and some temporarily reverted to tin. New North and Cheyyar facilities now ramping; double-digit growth expected in coming quarters.
Q. Update on medical dosing pens and ophthalmic products timeline?
Ophthalmic: trial molds done, commercial molds take 5-6 months so launch early CY27. Pens: exploring IP tie-up to cut development from 3 years to 1 year; if partnership works, revenue possible within a year; else 2-3 years.
Q. Why did finance cost rise 20% QoQ?
Raw material price spike (₹97 to ₹130/kg) increased working capital and inventory carrying cost; not term loans. If RM stabilises, working capital may ease slightly.
Q. Is paint volume growth sustainable? What is the full-year expectation?
Paint volume grew 10.8% in Q1, driven by Asian Paints IML shift; guidance for full-year paint volume growth 10-15%.
Q. Can we expect 19-20% EBITDA growth for the full year?
Yes, mix shift and efficiencies should deliver 18-20% EBITDA growth even with moderate volume growth.
Q. Semiconductor packaging entry — any update?
Longer-shot; exploring technology partners from Taiwan/Korea; at drawing-board stage, no immediate timeline.
Research and educational content only. Not investment advice.